Details for New Drug Application (NDA): 019715
✉ Email this page to a colleague
The generic ingredient in DIPENTUM is olsalazine sodium. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olsalazine sodium profile page.
Summary for 019715
Tradename: | DIPENTUM |
Applicant: | Mylan Spclt Viatris |
Ingredient: | olsalazine sodium |
Patents: | 0 |
Suppliers and Packaging for NDA: 019715
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
DIPENTUM | olsalazine sodium | CAPSULE;ORAL | 019715 | NDA | Meda Pharmaceuticals Inc. | 0037-6860 | 0037-6860-10 | 100 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC (0037-6860-10) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 250MG | ||||
Approval Date: | Jul 31, 1990 | TE: | RLD: | Yes |
Expired US Patents for NDA 019715
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Mylan Spclt Viatris | DIPENTUM | olsalazine sodium | CAPSULE;ORAL | 019715-001 | Jul 31, 1990 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription